Macular edema is a significant risk factor for visual impairment. Such pathological conditions often traced back to the occlusion of retinal veins. This synopsis is based on the guideline by National Institute for Health and Care Excellence (NICE) that explains Ranibizumab therapy for visual impairment Guidance: Condition The guideline indicated the following conditions when Ranibizumab can be safely used: Visual impairment caused by macular edema: Following the occlusion of the central vein Following the occlusion of the branch retinal vein (if photocoagulation is ineffective or unsuitable due to the extent of macular hemorrhage) Treatment Dose Ranibizumab is administered as a single 0.5 mg intravitreal injection.
Each vial of ranibizumab contains 2.3 mg in 0.23 ml; overfilling is considered necessary to achieve an injectable dose of 0.5 mg. Treatment course of Ranibizumab Monthly…
